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Gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the
mammalian central nervous system, is also known to be important for brain development.
Therefore, disturbances of GABA receptor (GABA-R) mediated signaling (GABA-R signal)
during brain development may influence normal brain maturation and cause late-onset
brain malfunctions. In this study, we examined whether the stimulation of the GABA-R
signal during brain development induces late-onset adverse effects on the brain in
adult male mice. To stimulate the GABA-R signal, we used either the benzodiazepine
sleep-inducing drug triazolam (TZ) or the non-benzodiazepine drug zolpidem (ZP). We
detected learning and memory deficits in mice treated with TZ during the juvenile period,
as seen in the fear conditioning test. On the other hand, ZP administration during the
juvenile period had little effect. In addition, decreased protein expression of GluR1 and
GluR4, which are excitatory neurotransmitter receptors, was detected in the hippocampi
of mice treated with TZ during the juvenile period. We measured mRNA expression of the
immediate early genes (IEGs), which are neuronal activity markers, in the hippocampus
shortly after the administration of TZ or ZP to juvenile mice. Decreased IEG expression
was detected in mice with juvenile TZ administration, but not in mice with juvenile ZP
administration. Our findings demonstrate that TZ administration during the juvenile period
can induce irreversible learning and memory deficits in adult mice. It may need to take
an extra care for the prescription of benzodiazepine sleep-inducing drugs to juveniles
because it might cause learning and memory deficits.
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INTRODUCTION
Normal brain development requires various neuronal signals must be activated at the appropriate
timing and with the proper extent in the developmental brain (Rice and Barone, 2000). Excitatory
glutamate receptor (Glu-R) signals and inhibitory gamma-aminobutyric acid (GABA) receptor
(GABA-R) signals are the most important neuronal signals in the adult brain. These neuronal
signals are also known to be important for brain development. These signals have roles in neuronal
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cellular proliferation and differentiation, neuronal migration,
the construction of neuronal circuits, and the reorganization of
neuronal circuits (Luján et al., 2005). Therefore, the stimulation
of these neuronal signals with external factors, such as chemical
compounds, may interfere with normal brain development
and result in late-onset functional deficits during adulthood.
We have previously reported that the transient activation of
Glu-R signals in the prenatal mouse brain with domoic acid
results in aberrant emotional behavior, as well as learning and
memory deficits, as revealed by a mouse behavioral battery
tests (BBT) (Tanemura et al., 2009). On the other hand, Haas
et al. have shown that prenatal GABA-R signal activation with
the anxiolytic drug Diazepam (DZP) leads to the inhibition
of neuronal migration and the disruption of cerebral cortex
neuronal circuits (Haas et al., 2013). In addition, Shen et al. have
shown that neonatal activation of GABA-R signals by DZP results
in increased anxiety-like behavior (Shen et al., 2012). However,
the behavioral tests applied in these studies were limited, and
their results were not analyzed in an integrated manner. We
therefore believe that analyses of several behavioral tests during
the adult stage following the activation of GABA-R signals during
brain development are critically needed.
In this study, we report the results of the BBT that we
conducted. These include the open field test, the light/dark
transition test, the elevated plus maze test, the contextual/cued
fear conditioning test, and the pre-pulse inhibition test.
The results of these tests will help us to understand the
effects of GABA-R signal activation during brain development
FIGURE 1 | Experimental schedule. This figure describes the experimental schedules for triazolam (TZ) and zolpidem (ZP) treatment. The gray arrow indicates
vehicle and the black arrows indicate TZ 1 mg/kg or ZP 50 mg/kg. All mice received the drug three times by gavage. The two ages of 2 weeks (2 w) and 11 weeks (11
w) were selected. TZ and ZP were administered to the mice at one of the two time points and vehicle was administered at the other two time points. The mice were
weaned at 4 weeks. Male mice were selected and were housed in new cages (4 mice per cage). A behavioral battery tests (BBT) was carried out starting at 12 weeks
of age. Each group consisted of eight mice (6 group, 48 mice total).
with the benzodiazepine (BZD) sleep-inducing drug triazolam
(TZ: original brand name “Halcion”) or the non-BZD drug
zolpidem (ZP: originally marketed as “Ambien” and available
worldwide under many brand names) on behavior during
the adult stage (Pakes et al., 1981; Holm and Goa, 2000).
These sleep-inducing drugs have similar pharmacokinetic and
pharmacodynamic effects in humans (Lobo and Greene, 1997).
They are preferentially used as drugs for the treatment of
insomnia owing to their lack of carryover effects on the
next day (Neubauer, 2007). Their reported side effects include
drug-dependence, withdrawal symptoms, psychiatric symptoms
(excitement stimulation, confusion, aggression, noctambulation,
hallucinations, delusions, and agitation), transient anterograde
amnesia before and after sleeping, or arousal during sleep (Pakes
et al., 1981; Jonas et al., 1992; Toner et al., 2000; Greenblatt
and Roth, 2012). Treatment of sleep disorders in children using
hypnotic drugs is common (Kahn et al., 1989; Stores, 1996;
Owens et al., 2003; Weiss and Garbutt, 2010; Felt and Chervin,
2014), although their safety in children has not been established
(FDA, 2008, 2013). These chemicals act by suppressing excitatory
neuronal activity by inducing hyperpolarization following the
cellular influx of chloride ions when they bind to GABA (A)-R
alpha and gamma receptors. GABA (A)-R is found as pentamers
of a combination of 19 subunits (α1–6, β1–3, γ1–3, δ, ǫ, θ, pi, and
ρ1–3). The BZD chemical TZ binds to GABA (A)–R α1, 2, 3, 5,
and 6 subtypes in any combination, along with the γ2 subtype.
The non-BZD chemical ZP binds only to combinations of GABA
(A)–R α1 and γ2 subtypes (Rudolph and Knoflach, 2011).
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MATERIALS AND METHODS
Animal Experiment
All animal experiments were conducted with permission from
the Animal Ethics Committee at the National Institute of Health
Sciences. Pregnant female C57BL/6NCrSlc mice at embryonic
day 11 were purchased from Japan SLC Inc. (Shizuoka, Japan).
The mice were housed in plastic cages and maintained under
a 12-h light/12-h dark cycle with water and chow (CRF-1,
Oriental Yeast Co. Ltd., Tokyo, Japan) provided ad libitum.
Triazolam (TZ: 8-chloro-6-(2-chlorophhenyl)-1-methyl-4H-1,
2, 4 -triazolo[4,3-a]-1, 4-benzodiazepine; Sigma Aldrich Co.
Steinheim, Germany), and Zolpidem (ZP: N,N,6-Trimethyl-
2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide; Sigma
Aldrich Co., Steinheim, Germany) were dissolved in 0.5% (w/v)
methyl cellulose solution (Wako Pure Chemical Industries, Ltd.
Osaka, Japan) and administered by gavage at the doses of 1
and 50 mg/kg. In the vehicle group, 0.5% (w/v) methyl cellulose
solution (MC) was administered by gavage. Administration and
experimental schedules are shown in Figure 1. Mice in the
Vehicle group (8 mice per experimental group, 16 mice total)
were treated with 0.5% (w/v) MC at 2 weeks and 11 weeks of age.
The TZ-2w group (8 mice) was treated with TZ at 2 weeks of age
and with 0.5% (w/v) MC at 11 weeks of age. The ZP-2w group (8
mice) was treated with ZP at 2 weeks of age and with 0.5% (w/v)
MC at 11 weeks of age. The TZ-11w group (8 mice) was treated
with 0.5% (w/v) MC at 2 weeks of age and with TZ at 11 weeks of
age. The ZP-11w group (8 mice) was treated with 0.5% (w/v) MC
at 2 weeks of age and with ZP at 11 weeks of age. Subsequently, a
series of BBT were conducted at 12 weeks of age. After the BBT,
the brains of the mice were dissected, and the hippocampus was
removed for biochemical analysis at 13 weeks of age.
Mouse Behavioral Battery Test
We conducted a behavioral battery test (BBT), including the open
field test (OF), the light/dark transition test (LD), the elevated
plus maze test (EP), the contextual/cued fear conditioning test
(FZ), and the additional pre-pulse inhibition test (PPI). For the
OF, LD, EP, and FZ methods details, refer to the Tanemura
et al. (2009). In the present study, we added the PPI further
for information processing analysis. Experimental apparatuses
and image analysis software was obtained from O’Hara & Co.,
Ltd., Japan. Image analysis software (Image OF4, Image LD2,
FIGURE 2 | Results of the open field (OF) test. (A,B) The scores of the OF test (total test time, 600 s) are shown. (Aa,Bc) Distance traveled (cm) during the test
period (600 s) is shown. (Ab,Bd) Time spent in the center area (seconds) is shown. (Ab) Statistically significant increases were detected in the TZ-11w group. (Ae,Bg)
Average speed (cm/total time) is shown. (Af,Bh) Distance per movement (cm) is shown. n = 8, mean ± SEM. Asterisk (*) indicates a statistically significant difference
(*p < 0.05, Student’s t-test) compared to the Vehicle group.
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Image EP2, and Image FZ2) were developed using the public
domain ImageJ program. All experiments were performed with
8 mice per group (TZ experimental: 3 groups, ZP experimental:
3 groups). We thus had 6 groups for a total of 48 mice. The
experimental tests were conducted between 13:30 and 16:30. The
level of background noise during BBT was about 50 dB. After
each trial, the apparatus was wiped and cleaned. The pre-pulse
inhibition test apparatus consists of a light source and a sound
system, and a startle measurement load cell. These are set into a
soundproof box. The software for the operation of the apparatus
and the data analysis is the SR-9040 (O’Hara & Co., Ltd., Tokyo,
Japan). The white background noise level is set to 70 dB in the
soundproof box. The mouse is put into a plastic cylinder and
kept there for 90 s before the test. The test schedule consists of
three blocks, and the total trial time is 30 min. Breakdown of each
block is as follows: 80, 85, 95, 100, 105, and 110 dB pulse × 3
(acclimation block), 120 dB pulse× 10 (acoustic startle response
block). The combinations of pre-pulse are 80–120, 85–120, 95–
120, 100–120, 105–120 dB, with a delay of 100 ms × 6 (pre-
pulse inhibition measurement block). These combinations were
presented in a pseudorandom order, such that each trial type was
presented once within a block. The inhibition ratio (%) of the
startle response is calculated as follows: (1–pre-pulse [80, 85, 95,
100, or 105 dB] startle response value / acoustic startle response
value)× 100.
Western Blotting
Hippocampal extracts were dissolved in Tris-buffered saline
(pH 7.4) containing protease inhibitors (Nacalai Tesque, Inc.,
Kyoto, Japan) and phosphatase inhibitors (Nacalai Tesque, Inc.,
Kyoto, Japan). Equal volume of the total protein solutions were
added to 2 × sample buffer solution (Nacalai Tesque, Inc.,
Kyoto, Japan). The amount of protein was quantified using
Qubit protein assay kits (Life Technologies Co., California,
USA). The protein samples (30 µg/well) were subjected
to SDS-PAGE (7.5% polyacrylamide), and transferred to a
nitrocellulose membrane. The membranes were blocked in
Blocking-one (Nacalai Tesque, Inc., Kyoto, Japan) at room
temperature for 90 min and incubated with primary antibodies,
such as those against acetyl-tubulin (sc-23950, Santa Cruz
Biotechnology, Inc., California, USA), MAP2 (sc-20172), GluR1
(T9026, Sigma Aldrich Co., Steinheim, Germany), and GluR4
(SAB450126) overnight at room temperature. The membranes
were then washed with phosphate buffered saline (pH 7.4)
with 0.05% Tween-20 (PBS-T). The membranes were then
incubated with peroxidase-conjugated secondary antibodies for
2 h at room temperature. After several PBS-T washes, the
membranes were incubated with chemi-lumi one L (Nacalai
Tesque, Inc., Kyoto, Japan) for signal production. The signal
was photographed using an LAS-3000 (Fujifilm Co., Ltd., Tokyo,
Japan). The intensity of each protein band was measured
FIGURE 3 | Results of the light/dark transition (LD) test. (A,B) The scores for the LD test (total test time, 360 s) are shown. (Aa,Bc) Time spent in the light box
(seconds). (Ab,Bd) Light box distance traveled (seconds) is shown. (Ae,Bg) The number of transitions between the dark box and the light box. (Af,Bh) Latency
(seconds) to enter the light box for the first time. No significant differences compared with the Vehicle group were detected in the LD. The number of mice per group
was eight and the scores are shown as the mean ± SEM.
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using the Gel Analyzer program in ImageJ, and normalized
to the intensity of the acetyl-tubulin band using the following
formula: (intensity of each protein band/acetyl-tubulin band
intensity) × 100. We present each normalized band intensity
as a percentage of its intensity in the Vehicle group. The
changes in protein expression associated with TZ and ZP
treatment were calculated as follows: Ratio (%) = (Vehicle,
TZ and ZP group individual value/Vehicle group average
value)× 100.
Quantitative RT-PCR
Duplicate homogenate hippocampal samples were treated with
DNaseI (amplification grade, Invitrogen Corp., Carlsbad, CA,
USA) for 15 min at room temperature. They were then
incubated with Super-Script II (Invitrogen) for 50 min at
42◦C for reverse transcription. Quantitative real time PCR was
performed using an ABI PRISM 7900 HT sequence detection
system (Applied Biosystems, Foster City, CA, USA) using SYBR
Premix Ex Taq (Takara Bio Inc., Japan) with initial denaturation
at 95◦C for 10 s followed by 45 cycles of 5 s at 95◦C and
60 s at 60◦C. Ct values were obtained. The primers were
synthesized by FASMAC Co., Ltd., Japan. Expression of genes
of interest was normalized to that of Actb and presented as
fold change over baseline using the delta-delta CT method.
Fold changes of relative gene expression levels compared to
those of Vehicle animals were calculated (Livak and Schmittgen,
2001).
Primers
Arc: forward 5′-TACCGTTAGCCCCTATGCCATC-3′, reverse
5′-TGATATTGCTGAGCCTCAACTG-3′
c-Fos: forward 5′-ATGGGCTCTCCTGTCAACACAC-3′, reverse
5′-ATGGCTGTCACCGTGGGGATAAAG-3′
Nr4a1: forward 5′- TTAAGAGGTGGGTCGGGTTC -3′, reverse
5′- GCAATCCTTCTCGCACACTA -3′
ActB: forward 5′-GGACTCATCGTACTCCTGCTT-3′, reverse
5′-GAGATTACTGCTCTGGCTCCT-3′.
Statistical Analysis
Statistical analysis was conducted using Prism 5.04 (SAS
Institute, California, USA). Data was analyzed using Student’s
unpaired t-tests. Values in graphs are expressed as the mean ±
standard error of the mean (SEM).
FIGURE 4 | Results of the elevated plus maze (EP) test. EP tests were conducted to analyze emotional behavioral changes in TZ- and ZP-treated mice. (A,B)
The scores of the EP test (total test time, 600 s) are shown. (Aa,Bc) Time spent in the open arm (seconds). (Ab,Bd) Time spent in the closed arm (seconds). (Ae,Bg)
Time spent in the center area (seconds). (Af,Bh) Total distance moved (cm). No significant differences with the Vehicle group were detected in the EP. The number of
mice per group was eight and the scores are shown as the mean ± SEM.
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FIGURE 5 | Results of the fear conditioning test. (A,B) Fear conditioning test was conducted to analyze the effects of TZ and ZP on learning and contextual
memory, i.e., place (test-box) and sound (cued tone). (Aa,d,Bg,j) The total conditioning time was 360 s. Three cycles consisting of a tone (30 s) and a mild foot shock
(Continued)
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FIGURE 5 | Continued
(arrows: 0.1 mA, 3 s) were carried out for each mouse after it was allowed to explore the box freely for 90 s. (Aa,Bg) The time course of the freezing % scores is
plotted for the conditioning test. As the cycles of the conditioning were repeated, the freezing percentages increased in the Vehicle group and in all groups other than
the TZ-2w group. This indicates successful conditioning. On the other hand, the freezing % remained low in the TZ-2w group. (Ad,Bj) The average freezing % scores
during the later period (180–360 s) of the conditioning test are shown. A significant decrease in freezing % was observed in the TZ-2w group. (Ab,e,Bh,k) Contextual
tests were conducted 24 h after the conditioning test to analyze the effects of triazolam on place memory function. (Ab,Bh) The time course of the freezing % scores
is plotted for the contextual test. The total time of the test is 360 s. (Ae,Bk) The average freezing % scores in the contextual test are shown. A significant decrease in
freezing % was detected in the TZ-2w group. (Ac,f,Bi,l) The cued test was conducted 24 h after the contextual test to analyze the effects of triazolam on cued
memory function. The total time of the test is 360 s. (Ac,Bi) The time course of the freezing % scores was plotted for the cued test. The tone was presented to the
mice during the later period of the test (180–360 s). (Af,Bl) The average freezing % scores for the first one minute period after the tone are presented. The freezing %
scores of the TZ-2w group were significantly lower than those of the Vehicle group. The number of mice per group was eight and the scores are shown as the mean ±
SEM. Asterisk (*) indicate statistically significant differences (*p < 0.05, Student’s t-test) compared to the Vehicle group.
FIGURE 6 | Results of the pre-pulse inhibition (PPI) test. (A,B) The pre-pulse inhibition test was conducted to analyze the effects of sleep-inducing drugs on
sensory information processing. The scores indicated the inhibition (%) of the startle response to a 120-dB sound with pre-pulse sounds of 90, 95, 100, and 105 dB
when compared to the response to a 120-dB sound without a pre-pulse sound. No significant differences were found in the PPI test. The number of mice per group
was eight and the scores are shown as the mean ± SEM.
RESULT
Results of Behavioral Battery Tests in the
TZ-11w, TZ-2w, ZP-11w, and ZP-2w
Groups
In the open field test (Figure 2), the total distance traveled
and the time spent in the center region were significantly
longer in the TZ-11w group (Figure 2Ab). Exposure to either
chemical did not lead to any changes in the results of the
light/dark transition test (Figure 3) or the elevated plus maze
test (Figure 4). In the fear conditioning test, only the TZ-2w
group did not show an increase in freezing % during the later
period of the conditioning trial (Figures 5Aa,d, Bg,j, p < 0.05).
In addition, in the contextual test, only the TZ-2w group had
significantly lower freezing percentages (Figures 5Ab,e, Bh,k, p
< 0.05). All other groups responded quickly to the tone and
showed high freezing responses, while mice in the TZ-2w group
had slower responses to the tone, which resulted in lower freezing
responses (Figures 5Ac,f, Bi,l, p < 0.05). These results indicate
that the administration of TZ during the juvenile period induces
deficits in learning and memory. Exposure to either chemical did
not lead to any changes in the results of the pre-pulse inhibition
test (Figure 6). Significant differences were not observed in any
of the tests in our BBT in the ZP-11w and ZP-2w groups. The
results of the series of BBT performed on the TZ-11w, TZ-2w, ZP-
11w, and ZP-2w groups during the adult stage are summarized in
Table 1.
Protein Expression in the Adult
Hippocampus in the TZ-11w, TZ-2w,
ZP-11w, and ZP-2w Groups
We analyzed expression of several proteins in the adult
mice hippocampus following juvenile or adult stage exposure
to triazolam or zolpidem using western blotting (Figure 7).
Although, no differences were detected in the TZ-11w, ZP-
2w, and ZP-11w groups, MAP2 (Figures 7A,Bb, p < 0.05)
was increased and GluR1 and GluR4 (Figures 7A,Ba,b, p <
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TABLE 1 | A summary for the behavioral change at adult stage with different developmental exposure of triazolam 1 mg/kg B.W. and zolpidem 50 mg/kg
B.W.
Test name Behavioral tasks Triazolam 1 mg/kg Zolpidem 50 mg/kg
TZ-11w TZ-2w ZP-11w ZP-2w
Open field Distance traveled 1.14 1.23 0.90 0.97
Center region time 1.72* 1.51 1.31 1.20
Average speed 1.14 1.23 0.90 0.97
Moving speed 1.03 1.09 0.96 0.97
Moving episode number 0.99 0.98 1.00 0.97
Total movement duration 1.12* 1.14* 0.93 1.00
Distance per movement 1.15 1.29 0.91 1.00
Duration per movement 1.14 1.19 0.94 1.03
Light/Dark transition Dark distance 0.95 0.96 0.86 0.89
Light distance 1.08 0.92 1.06 1.18
Dark time 0.95 1.03 0.96 0.92
Light time 1.12 0.97 1.19 1.28
Number of transitions 1.00 0.97 0.93 1.04
Latency to enter light 0.81 0.87 1.47 1.31
Elevated plus maze Total distance 1.01 1.08 1.21 1.24
Total center time 0.91 1.05 1.22 1.73
Total open area 1.02 1.05 1.45 1.43
Total close area 1.03 0.98 0.90 0.75
Total arm select number 0.90 0.97 1.41 1.47
Fear conditioning Total conditioning freezing % 0.83 0.27 1.57 0.91
Conditioning 5–6 min freezing % 0.52 0.24* 1.39 1.02
Total contextual freezing % 0.82 0.47* 1.43 0.72
Cued tone 3–6 min freezing % 0.89 0.72 0.98 0.96
Cued tone 3–4 min freezing % 0.92 0.64* 0.92 0.93
Pre-pulse inhibition Pre-pulse 90 dB 1.07 1.28 1.32 1.38
Pre-pulse 95 dB 1.19 0.98 0.78 1.24
Pre-pulse 100 dB 1.07 1.05 0.90 0.89
The number indicates the fold change to vehicle and the asterisk indicates for the tests with the statistically significant difference to vehicle group [*p < 0.05 (Student’s t -test)].
0.05) were decreased in the TZ-2w group. Both GluR1 and
GluR4 belong to the AMPA-type glutamate receptor family
and are known to be necessary for long-term potentiation in
the hippocampus (Sanderson et al., 2008; Lee and Kirkwood,
2011). Therefore, decreases in the levels of GluR1 and
GluR4 may be important mechanisms underlying the learning
and memory deficits in mice exposed during the juvenile
period.
mRNA Expression of Immediate Early
Response Genes (IEGs) in the TZ-2w and
ZP-2w Groups
We analyzed mRNA expression levels of IEGs (Arc, c-fos,
and Nr4a1) in the hippocampus shortly (8 h) after TZ and
ZP administration during the juvenile period. We observed
decreasedmRNA expression of IEGs in the TZ-2w group, but not
in the ZP-2w group (Figure 8).
DISCUSSION
In this study, we analyzed the late-onset effects of the stimulation
of the GABA-R signal using a behavioral battery tests (BBT) and
several biochemical assays. We stimulated the GABA-R signal of
mice by the oral administration of the sleep-inducing drugs TZ
(1 mg/kg body weight [B.W.]) or ZP (50 mg/kg B.W.) during
juvenile (TZ-2w, ZP-2w) and adult stages (TZ-11w, ZP-11w).
The results of the BBT indicate that spontaneous activity, as
measured in the open field test, was significantly increased in
the TZ-11w group. Reactivity to a novel environment may be
changed in mice exposed to TZ during adulthood. On the other
hand, deficits in learning and memory were detected by the fear
conditioning test only in the TZ-2w group. The freezing response
was decreased in all three stages (conditioning test, contextual
test, and cued test) of the fear conditioning test. Although, the
TZ-11w, ZP-11w, and ZP-2w groups had increases in freezing
% as the cycles of tone and mild foot-shock were repeated, the
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FIGURE 7 | Protein expression in the hippocampus during the adult stage following exposure to TZ and ZP during development. The expression levels of
several proteins were analyzed by western blotting to explore the effects of triazolam on the hippocampus during adulthood. (A) Acetyl-tubulin and AMPA-type
glutamate receptors GluR1 and GluR4, as well as the neuronal cytoskeletal marker MAP2. (Ba–c) The expression of each protein was normalized to that of
acetyl-tubulin expression and its ratio (%) to the expression in the Vehicle group is shown. The number of samples was two and the value is shown as the mean ±
SEM. Asterisk (*) indicate statistically significant differences (*p < 0.05, Student’s t-test) compared to the Vehicle group.
TZ-2w group did not have an increase in freezing %, even during
the later period of the test. These results may indicate that TZ-
2w mice lose their ability to make short-term memories, which
are needed for quick responses in this situation. In addition, TZ-
2wmice had significantly lower scores in the contextual test. This
may indicate deficits in spatial memory (Clark and Squire, 1998).
In the cued test, a delay of the freezing response to the tone was
detected in the TZ-2w group, which may indicate mild deficits
in cued memory. We believe that these learning and memory
deficits are the most serious effects of TZ treatment in the TZ-2w
group.
To identify the molecular mechanisms underlying the late-
onset learning and memory deficits, we first analyzed the
expressions of several proteins in the hippocampus. We observed
late-onset protein expression changes in the TZ-2w group. For
example, MAP2 expression was increased in TZ-2w mice. MAP2
is a protein specifically expressed in the dendrites of neurons
and plays an important role in the stabilization of tubulin
structure in neuronal filaments (Caceres et al., 1983). There are
also several reports of decreases in MAP2 levels in Alzheimer’s
disease and Parkinson’s disease (Li et al., 2008; Liu et al., 2011).
However, no increases in MAP2 levels have been reported thus
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FIGURE 8 | Comparisons of immediate early response gene (IEG) mRNA expression levels in the hippocampus shortly after TZ or ZP exposure. Eight
hours after TZ or ZP administration to juvenile (2-week-old) mice, we examined the mRNA expression levels of multiple IEGs in the hippocampus. Significant
decreases in the expressions of (A) Arc, (B) c-Fos, and (C) Nr4a1 were observed in the TZ-2w group. The number of the samples in each group was three and the
values are shown as mean ± SEM. Asterisk (*) indicate statistically significant differences (*p < 0.05, Student’s t-test) compared to the Vehicle group.
far. It is therefore still unclear how this increase in MAP2
levels relates to the deficits induced by triazolam. In addition,
the expression levels of GluR1 and GluR4 were decreased in
the TZ-2w group. GluR1 and GluR4 are AMPA-type glutamate
receptors and are known to be important for learning and
memory, as they induce long-term potentiation and synaptic
plasticity (Sanderson et al., 2008; Lee and Kirkwood, 2011).
Therefore, the deficits of learning and memory in the adult
stage in neonatally exposed mice may be related to decreases
in GluR1 and GluR4 levels. None of the ZP-treated groups and
TZ-11w groups had changes in MAP2, GluR1, or GluR4 protein
expression.
We hypothesize that TZmay have greater inhibitory effects on
the hippocampus during the juvenile period and that may be a
trigger of learning and memory deficits. Therefore, we measured
changes in IEG mRNA expression in the hippocampi of juvenile
mice shortly after TZ or ZP exposure (8 h). As expected, TZ
had a greater inhibitory effect on the juvenile hippocampus than
ZP. Indeed, the expression levels of all three IEGs (Arc, c-fos,
and Nr4a1) were decreased in response to TZ treatment. IEGs
are known to be induced rapidly following neuronal activation
and are considered as markers of activated neurons (Sheng
and Greenberg, 1990). The TZ-specific suppression of neuronal
activity during the juvenile period may thus be responsible for
the TZ-specific learning and memory deficits.
In summary, our findings demonstrate that the BZD sleep-
inducing drug TZ can lead to learning and memory deficits
with juvenile exposure. In contrast, ZP, which is a non-BZD, did
not induce deficits in brain functional development. Decreased
IEG expression was detected in mice treated with TZ during
the juvenile period, but not in mice treated with ZP during
the juvenile period. Therefore, we suggest that decreased IEG
expression may be one of the triggers for the long-lasting adverse
effects of TZ on the brain. The learning and memory deficits
induced by TZ may be dependent on the timing of the exposure,
as GABA-R signal has different functions in different brain
developmental stages and in different brain regions containing
GABA-Rs (Rice and Barone, 2000). GABA-R signal is reported
to have a critical role in the reconstruction of synapses during
the juvenile period (Steward and Falk, 1986; Herschkowitz et al.,
1997). Therefore, juvenile exposure to TZ may interfere with
synapse reconstruction and affect the proper development of
learning and memory.
We have previously reported the aberration of emotional
behavior associated with deficits in learning andmemory in adult
male mice treated with domoic acid (the chemical compound
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for the excessive activation of glutamate receptor mediated
signal; Glu-R signal) at prenatal period by the administration
to pregnant female mice (Tanemura et al., 2009). Nevertheless,
we could not find the correlativity with this study using
TZ. The following points can be given as that reasons. In
previous study, we used mice in prenatal period does not
correspond in the degree of maturation of hippocampus from
juvenile period (Rice and Barone, 2000; Luján et al., 2005).
Moreover, the domoic acid and TZ are completely different
mechanism of action. We demonstrated that TZ administration
cause the IEGs expression inhibitory in the juvenile period
hippocampus. However, the domoic acid administration is
known to increase IEG expression in hippocampus (Scallet
et al., 2004). For these reasons, current study cannot be
directly compared with previous one. We guessed that there
might be several differences between the effects induced by
disturbances of GABA-R and Glu-R signals, as each neuronal
signal has the particular function to construct the neuronal
circuits and reorganization depending on brain development
(Steward and Falk, 1986; Rice and Barone, 2000; Luján et al.,
2005). In addition, we guessed that the various aberrations
of behavioral manners might be induced by the various
disturbances of neural signals by the neuroactive chemical
compounds.
In conclusion, our study indicates that juvenile TZ exposure
may lead to learning and memory deficits. GABA-R agonists,
such as BZD, are used for the treatment of both sleep disorders
and anxiety disorders in both adults and children (Chevreuil
et al., 2010; Weiss and Garbutt, 2010; Pelayo and Yuen,
2012). Therefore, considering the possible influence of GABA-
R agonists on brain development, their careful prescription to
children is warranted.
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